Top

Published in:

01-04-2015 | Research

Prolactin and Prolactin Receptor Expression in Cervical Intraepithelial Neoplasia and Cancer

Published in: Pathology & Oncology Research | Issue 2/2015

Abstract

Prolactin receptor (PRLR) overexpression could play a role in tumorigenesis. The aim of this study was to determine prolactin (PRL) and PRLR expression in biopsies from patients with precursor lesions and uterine cervical cancer. PRLR expression was analyzed in 63 paraffin-embedded biopsies of uterine cervical tissue. In total, eleven low-grade squamous intraepithelial lesions (LSIL), 23 high-grade squamous intraepithelial lesions (HSIL), 21 uterine cervical cancers (UCC) and 8 normal epithelium (NE) were examined using immunoperoxidase staining and Western blot analysis. Additionally, PRL expression was identified in human cervical cancer serum and tissues. The PRLR expression was found to be significantly increased in cervical cancer in comparison with normal tissue and precursor lesions (P < 0.0003). The presence of the long isoform of the PRLR was observed only in cervical cancer tissues. Serum PRL levels were normal in all samples and local prolactin expression was similar in precursor lesions and cervical cancer by Western blot analysis. Our data suggest a possible role for PRLR in the progression of cervical cancer.

zur Hausen H. Papillomavirus infections--a major cause of human cancers. Biochimica et biophysica acta. 1996;1288 (2):F55-78. Epub 1996/10/09.

Neville MC, McFadden TB, Forsyth I (2002) Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia 7(1):49–66, Epub 2002/08/06CrossRefPubMed

Rui H, Kirken RA, Farrar WL (1994) Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J Biol Chem 269(7):5364–8, Epub 1994/02/18PubMed

Al-Sakkaf KA, Dobson PR, Brown BL (1997) Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells. J Mol Endocrinol 19(3):347–50, Epub 1998/02/14CrossRefPubMed

Das R, Vonderhaar BK (1996) Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat 40(2):141–9, Epub 1996/01/01CrossRefPubMed

Nohara A, Ohmichi M, Koike K, Jikihara H, Kimura A, Masuhara K et al (1997) Prolactin stimulates mitogen-activated protein kinase in human leiomyoma cells. Biochem Biophys Res Commun 238(2):473–7, Epub 1997/09/23CrossRefPubMed

Ben-Jonathan N, Lapensee CR, Lapensee EW. What Can We Learn from Rodents about Prolactin in Humans? Endocr Rev. 2007.

McHale K, Tomaszewski JE, Puthiyaveettil R, Livolsi VA, Clevenger CV (2008) Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 21(5):565–71, Epub 2008/02/05CrossRef

Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE et al (1999) Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 154(3):863–70, Epub 1999/03/18CrossRefPubMedCentralPubMed

10.

Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J et al (2009) Biological significance of prolactin in gynecologic cancers. Cancer Res 69(12):5226–33, Epub 2009/06/06CrossRefPubMedCentralPubMed

11.

Gonzalez-Lucano LR, Munoz-Valle JF, Ascencio-Cedillo R, Dominguez-Rosales JA, Lopez-Rincon G, Del Toro-Arreola S et al (2012) Increased expression of the prolactin receptor is associated with malignant laryngeal tumors. Experimental and therapeutic medicine 3(4):603–7, Epub 2012/09/13PubMedCentralPubMed

12.

Macfee MS, McQueen J, Strayer DE (1987) Immunocytochemical localization of prolactin in carcinoma of the cervix. Gynecol Oncol 26(3):314–8, Epub 1987/03/01CrossRefPubMed

13.

Perumal BG, Moodley J, Pegoraro RJ (1998) Prolactin as a tumour marker in cancer of the cervix. J Obstet Gynaecol 18(3):260–2, Epub 2004/10/30CrossRefPubMed

14.

Harbaum L, Pollheimer MJ, Bauernhofer T, Kornprat P, Lindtner RA, Schlemmer A et al (2010) Clinicopathological significance of prolactin receptor expression in colorectal carcinoma and corresponding metastases. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 23(7):961–71, Epub 2010/05/11CrossRef

15.

Strukov EL, Safronnikova NR, Bobrov Iu F, Gamaiunova VB, Bokhman Ia V, Dil'man VM. [Hyperprolactinemia as a marker of the progression of cervical cancer]. Voprosy onkologii. 1990;36 (7):831–5. Epub 1990/01/01. Giperprolaktinemiia kak marker progressii raka sheiki matki.

16.

Hsu CT, Yu MH, Lee CY, Jong HL, Yeh MY (1992) Ectopic production of prolactin in uterine cervical carcinoma. Gynecol Oncol 44(2):166–71, Epub 1992/02/01CrossRefPubMed

17.

Shoupe D, Montz FJ, Kletzky OA, DiZerega GS (1983) Prolactin molecular heterogeneity. Response to thyrotropin-releasing hormone stimulation of concanavalin A-bound and -unbound immunoassayable prolactin during human pregnancy. Am J Obstet Gynecol 147(5):482–7, Epub 1983/11/01PubMed

18.

Pellegrini I, Lebrun JJ, Ali S, Kelly PA (1992) Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol 6(7):1023–31, Epub 1992/07/01PubMed

19.

Champier J, Claustrat B, Sassolas G, Berger M (1987) Detection and enzymatic deglycosylation of a glycosylated variant of prolactin in human plasma. FEBS Lett 212(2):220–4, Epub 1987/02/23CrossRefPubMed

20.

Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S et al (1992) Prolactin synthesized and secreted by human peripheral blood mononuclear cells: an autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci U S A 89(16):7713–6, Epub 1992/08/15CrossRefPubMedCentralPubMed

21.

Paraiba DB, Soares CR, Bartolini P, Arthuso FS, Borba EF, Bonfa E et al (2010) Lymphocytic prolactin does not contribute to systemic lupus erythematosus hyperprolactinemia. Clin Exp Rheumatol 28(6):866–72, Epub 2011/01/06PubMed

22.

Lopez-Rincon G, Pereira-Suarez AL, Del Toro-Arreola S, Sanchez-Hernandez PE, Ochoa-Zarzosa A, Munoz-Valle JF et al (2013) Lipopolysaccharide induces the expression of an autocrine prolactin loop enhancing inflammatory response in monocytes. J Inflamm (Lond) 10(1):24, Epub 2013/06/05CrossRefPubMedCentral

23.

Ginsburg E, Vonderhaar BK (1995) Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 55(12):2591–5, Epub 1995/06/15PubMed

24.

Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T et al (2007) Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 148(7):3089–101, Epub 2007/04/07CrossRefPubMed

25.

Lopez-Pulido EI, Muñoz-Valle JF, Del Toro-Arreola S, Jave-Suárez LF, Bueno-Topete MR, Estrada-Chávez C, Pereira-Suárez AL (2013) High expression of prolactin receptor is associated with cell survival in cervical cancer cells. Cancer Cell Int 13(1):103CrossRefPubMedCentralPubMed

26.

Kossiakoff AA (2004) The structural basis for biological signaling, regulation, and specificity in the growth hormone-prolactin system of hormones and receptors. Adv Protein Chem 68:147–69, Epub 2004/10/27CrossRefPubMed

27.

Meng J, Tsai-Morris CH, Dufau ML (2004) Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma. Cancer Res 64(16):5677–82, Epub 2004/08/18CrossRefPubMed

28.

Huang KT, Walker AM (2010) Long term increased expression of the short form 1b prolactin receptor in PC-3 human prostate cancer cells decreases cell growth and migration, and causes multiple changes in gene expression consistent with reduced invasive capacity. Prostate 70(1):37–47, Epub 2009/09/10CrossRefPubMedCentralPubMed

29.

Varghese B, Barriere H, Carbone CJ, Banerjee A, Swaminathan G, Plotnikov A et al (2008) Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway. Mol Cell Biol 28(17):5275–87, Epub 2008/06/25CrossRefPubMedCentralPubMed

30.

Plotnikov A, Li Y, Tran TH, Tang W, Palazzo JP, Rui H et al (2008) Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor. Cancer Res 68(5):1354–61, Epub 2008/03/05CrossRefPubMed

31.

Li Y, Clevenger CV, Minkovsky N, Kumar KG, Raghunath PN, Tomaszewski JE et al (2006) Stabilization of prolactin receptor in breast cancer cells. Oncogene 25(13):1896–902, Epub 2005/11/10CrossRefPubMed

Title: Prolactin and Prolactin Receptor Expression in Cervical Intraepithelial Neoplasia and Cancer
Publication date: 01-04-2015
Published in: Pathology & Oncology Research / Issue 2/2015
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9814-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations

Overexpression of Wild-Type p53-Induced Phosphatase 1 Confers Poor Prognosis of Patients with Nasopharyngeal Carcinoma

A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin

Tumor Necrosis Factor Alpha (−238 / −308) and TNFRII-VNTR (−322) Polymorphisms as Genetic Biomarkers of Susceptibility to Develop Cervical Cancer Among Tunisians

Pericardial Tamponade Caused by Tumor Hemorrhage – a Rare Complication of Metastatic Testicular Choriocarcinoma

High Phosphorylation Status of AKT/mTOR Signal in DESI2-Reduced Pancreatic Ductal Adenocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer